Mark A. Bryniarski, PhD, BS/MS
Mark A. Bryniarski is a senior principal scientist in the Department of Pharmacokinetics and Drug
Metabolism at Amgen. He received his BS/MS in pharmacology, a PhD in pharmaceutical sciences, and
completed postdoctoral training followed by a research assistant professor appointment, all at the
University at Buffalo in Buffalo, NY. His research at Amgen since joining in 2020 centers on cellular
protein handling, with a focus on characterizing the mechanisms driving the target-independent absorption
and disposition of monoclonal antibodies and Fc-based therapeutics. He also collaborates extensively to
develop and apply innovative cell-based approaches for predicting large-molecule pharmacokinetic
properties.
Md Tariqul Haque Tuhin, PhD
Tariqul Haque Tuhin, PhD, is a Senior Scientist in the Department of Pharmacokinetics and Drug
Metabolism–Bioanalytical at Amgen. He earned his BS and MS from the University of Dhaka, Bangladesh, and
completed his PhD in Pharmaceutical and Chemical Sciences at the University of the Pacific, California.
Following a postdoctoral fellowship, he transitioned into his current role at Amgen. Dr. Tuhin’s research
focuses on developing in vitro ADME assay toolkits for the study of biologics, employing robust
cell-based approaches to establish in vitro to in vivo correlations and advance characterization of
therapeutic proteins.
Co-Authors: Timothy M. Acker, Devin L. Wakefield, Panijaya (Gemy) Sethaputra, Kevin D. Cook,
Marcus Soto, Manuel Ponce, Ronya Primack, Aditya Jagarapu, Edward L. LaGory, and Kip P. Conner
Paper Title: Cellular Neonatal Fc Receptor Recycling Efficiencies Can Differentiate
Target-Independent Clearance Mechanisms of Monoclonal Antibodies